¤@¢¯¤»¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ®ø¤Æ¬ì

(B) 1. ¤@¦ì¯f¤H³Q®aÄÝ°e¦Ü«æ¶E«Ç¡A¦Û¶D¤W¸¡¤¤¥¡¯kµh¤w¦³3¤Ñ¡A¥­½ö·|§óµh¡A¦ñ¦³¹Ã¦R²{¶H¡CÃö©ó³o¦ì¯f¤H¡A¤U¦C±Ô­z¦óªÌ¿ù»~¡H
A.©â¦åÀËÅç Liapse ¸û¨ã¶EÂ_©Ê
B.­Y¦å¤¤ Amylase ¥¿±`,§Y¥i±Æ°£«æ©Ê¯ØŦª¢¤§¥i¯à©Ê
C.À³ª`·N¨ä¦å¤¤ triglyceride ¬O§_¶W¹L1000 mg/dL
D.À³ª`·N¨ä¸y³¡¬O§_¦³ Turner's sign
E.À³¸ß°Ý¨ä¥Ø«e¬O§_¦³ªA¥Î Furosemide, Hydrochlorothiazide, 6-Mercaptopurine/azathioprine µ¥ÃĪ«
 
(C) 2. ¦³Ãö Macroamylasemia¤§±Ô­z¡A¦óªÌ¿ù»~?
A.³o¬O¥Ñ©ó amylase multimers µLªk¥Ñ¦å¤¤±Æ¦Ü§¿¤¤©Ò­P
B.¦å¤¤ amylase ¿@«×·|²§±`¤W¤É
C.¦å¤¤ Lipase ³q±`¤]·|²§±`¤É°ª
D.Macroamylase ¥i¥Î chromatography °»´ú¥X¨Ó
E.¯f¤H³q±`¨S¦³¸¡µh
 
(A) 3. ¤U¦C¦U¶µ±Ô­z¡A¦óªÌ¥¿½T¡H
A.«æ©Ê¸¡Âm( < 2¶g) ¯f¤H­Y¦³bloody stool ©Îµo¿N >38.5 C ®É¡AÀ³¸Ô¬d¨ä­ì¦]
B.³ÌªñªA¥Î§Ü¥Í¯À¦Ó¾É­P«æ©Ê¸¡Âm¡A¤£¥²¶i¤@¨B¸Ô¬d¯f¦]
C.Osmotic diarrhea ¯f¤H¤§¤j«K¶q³q±`¤j©ó 1L/¤Ñ¡A¸T­¹§Y·|°±¤î¸¡Âm
D.Secretory diarrhea ¯f¤H¤§¤j«K¶q³q±`¤p©ó 1L/¤Ñ¡A§Y«K¸T­¹¤´·|¥X²{¸¡Âm
E.Small intestinal bacterial overgrowth ¸û¤Öµo¥Í©óintestinal motility²§±`(dysmotility) ¤§¯f¤H¡A¦p¡Gautonomic neuropathy
 
(D) 4. ¦³ÃöC«¬¨xª¢¤§±Ô­z¡A¦óªÌ¥¿½T¡H(1)¸g¥ÑÅé²G¶Ç¬V¡F(2)«æ©ÊC«¬¨xª¢¦h¼Æ¨S¯gª¬¡A¤£©ö¹îı¡F(3)¥Ø«e¤w¦³¬Ì­]¥i¨Ñ¹w¨¾¡F(4)°·±d¦¨¦~¤H¿©±w«æ©ÊC«¬¨xª¢¡A­Y¥¼ªvÀø¡A¬ù20% ·|Åܦ¨ºC©Ê¨xª¢¡F(5)ºC©ÊC«¬¨xª¢±wªÌ¡A­Y¥¼ªvÀø¡A20-30¦~«á¬ù¦³20-30% ·|ºtÅܦ¨¨xµw¤Æ¡F(6)¥Ø«e¨xÀù¯f¤H¤§¯f¦]¬°ºC©ÊC«¬¨xª¢¤§¤ñ¨Ò·U¨Ó·U°ª¡F(7)ºC©ÊC«¬¨xª¢±wªÌ¤§Á{§É¯fª¬¶È«]­­¦b¨xŦ
A.(1)+(2)+(3)+(4)
B.(2)+(4)+(5)+(7)
C.(3)+(5)+(6)+(7)
D.(1)+(2)+(5)+(6)
E.(4)+(5)+(6)+(7)
 
(C) 5. ¦³ÃöºC©ÊC«¬¨xª¢ªvÀø¤§±Ô­z¡A¦óªÌ¿ù»~¡H(1)ªø®Ä«¬¤zÂZ¯À (PEG IFN) ¨Ö¥ÎRibavirin ¥Ø«e¤´¬OªvÀø¥D¬y¡A¯S§O¬O¦bC¨x¯f¬r°ò¦]«¬²Ä¤@«¬±wªÌ¡F(2)ªø®Ä«¬¤zÂZ¯À (PEG IFN) ¨Ö¥ÎRibavirin¤§°Æ§@¥Î¥]¬A¡GÃþ¦ü¬y·P¤§¯gª¬¡A¥Õ¦å²y (¤¤©Ê²y) ­°§C¡B³h¦å¡F(3)ªø®Ä«¬¤zÂZ¯À (PEG IFN) ¨Ö¥ÎRibavirin¤§°Æ§@¥Î¤£¥]¬A¡G¦ÛÅé§K¬Ì¯e¯f (¤×¨ä¬O¥Òª¬¸¢ª¢)¡B¼~Æ{¡F(4)§K¤zÂZ¯À¥þ¤fªAC¨xÃĪ«Ãþ (Direct Acting Antiviral Agents, DAAs) ¤§°Æ§@¥Î¸û¤Ö¥B»´·L¡A¥]¬A¡G­Â«å¡BÀYµh¡B¥Ö½§ª¢¡BºÎ¯v»Ùê¡F(5)DAAs¹ïC¨x¯f¬r°ò¦]«¬²Ä¤G«¬±wªÌ¤§ªv¡²v¥i¹F¤E¦¨¤­¥H¤W¡F(6)¨C¤@ºØDAA¬Ò¥i¥Î©ó¨x¥\¯à¤w¥¢¥NÀv¤§¨xµw¤Æ¯f¤H(decompensated cirrhotic patients)¡F(7)DAAs¤§¨Ï¥Î»Ý¯S§Oª`·NÃĪ«¥æ¤¬§@¥Î(Drug-Drug Interactions)
A.(7)+(6)+(5)+(3)
B.(1)+(3)+(4)+(7)
C.(1)+(3)+(5)+(6)
D.(2)+(4)+(6)+(7)
E.(3)+(4)+(6)+(7)
 
(D) 6. Ãö©ó«æ©Ê¨xª¢¥i¯à¯f¦]¤§¶EÂ_¡A¤U¦C²Õ¦X¦óªÌ¥¿½T¡H(1)A«¬¨xª¢¡GIgG Anti-HAV¡F(2)B«¬¨xª¢¡GHBsAg, HBV DNA¡F(3)C«¬¨xª¢¡GAnti-HCV¡A HCV RNA¡F(4)Wilson's disease: ferritin, transferrin saturation¡F(5)Autoimmune hepatitis: Antinuclear antibody (ANA), smooth muscle antibody¡F(6)Primary biliary cirrhosis: Mitochondrial antibody
A.(1)+(3)+(5)+(6)
B.(2)+(3)+(4)+(5)
C.(3)+(4)+(5)+(6)
D.(2)+(3)+(5)+(6)
E.(1)+(2)+(3)+(5)
 
(A) 7. ¤@¦ìºC©ÊB«¬¨xª¢¤k©Ê±wªÌ¡A¦]¯f±¡©Ò»ÝªA¥Î Entecavir (Baraclude) ªvÀø¤w¦³¨â¦~¤§¤[¡A¨äALT¤ÎAST¤]¤@ª½ºû«ù¦b¥¿±`½d³ò¤º¡C¦ý¬O³Ìªñ¤@¦¸ÀËÅçµo²{ALT=100 (<41) U/L, AST=70 (< 31) U/L, HBV viral load: undetectable, Anti-HCV (+); HCV RNA: undetectable, Anti-HDV (-)¡C¤U¦C±Ô­z¦óªÌ¿ù»~¡H
A.¦¹¯f¤HÅ餺¤§B«¬¨xª¢¯f¬r¹ï entecavir ¤w²£¥Í§ÜÃÄ©Ê
B.¦¹¯f¤H¤£¬OC«¬¨xª¢¯f¬r (HCV) superinfection
C.¦¹¯f¤H¤£¬OD«¬¨xª¢¯f¬r (HDV) superinfection
D.À³¥[Åç IgM Anti-HAV
E.À³¥[Åç Antinuclear antibody (ANA)¤ÎSmooth muscle antibody
 
(E) 8. ¦³ÃöºC©ÊB«¬¨xª¢¯S²§©ÊªvÀø (PEG Interferon¤Î¤fªA§ÜB¨x¯f¬rÃĪ«) ¤§±Ô­z¡A¦óªÌ¿ù»~¡H(1)HBeAg (+) ±wªÌ¡AµL¨xµw¤Æ¡AULN < ALT < 2X ULN (upper limit of normal range)¡AÀ³¶}©l±µ¨üªvÀø¡F(2)HBeAg (-) ±wªÌ¡A­Y HBV DNA ¡Ù 2000 IU/mL¡A¥B¥b¦~¤º¦³¨â¦¸ ALT > 2X ULN (©¼¦¹¶¡¹j3­Ó¤ë¥H¤W)¡AÀ³¶}©l±µ¨üªvÀø¡F(3)¨xµw¤Æ±wªÌ¡A­YHBV DNA ¡Ù 10000 IU/mL¡AÀ³¶}©l±µ¨üªvÀø¡F(4)¨xµw¤Æ±wªÌ¡A¤w¥¢¥h¥NÀv(decompensated liver cirrhosis)¡A¤£½×HBV DNAÀË´úµ²ªG¬°¦ó¡AÀ³¶}©l±µ¨üªvÀø¡F(5)¦~»´¥Í¨|¦~ÄÖ¤§±wªÌ¡AÀu¥ý¦Ò¼{¤fªA§ÜB¨x¯f¬rÃĪ«¡F(6)­Y¦³«æ©Êµo§@¯f±¡¡A¥BBilirubin (T)=10.5 (< 1.0), PT=17.5 (< 11), À³¾¨³tµ¹¤©PEG InterferonªvÀø
A.(1)+(3)+(5)
B.(2)+(3)+(4)+(6)
C.(3)+(4)+(5)
D.(2)+(3)+(5)+(6)
E.(1)+(4)+(5)+(6)
 
(A) 9. ¨xµw¤Æ¤w¦³¦h¦~ªº¯f¤H³Ìªñ±`¦]¨x©Ê¸£¯fÅܦí°|¡C¨ä¨xŦ´Ý¦s¥\¯à (liver reserve) ¨ÃµL©úÅã´c¤Æ¡F¦í°|¤¤¥ç¬d¤£¥X¦UºØ»¤¦] (precipitating factor)¡C¥L¤@ª½©T©w³Ü lactulose ¨C¤Ñ3¦¸¡A¨C¦¸20 ml¡A¤@¤Ñ¦³3~4¦¸¤j«K¡F¨C¤Ñ­¹¥Îªº³J¥Õ½è¥ç¾A¤¤¡C¥[¥Î¤U¦C¦óºØÃĪ«¡A¦óªÌ¦³§U©ó´î¤Ö¨x©Ê¸£¯fÅܵo¥Í¤§ÀW²v¥B¤£·|¦³©úÅã°Æ§@¥Î¡H
A.Rifaximin
B.Metronidazole
C.Neomycin
D.Ciprofloxain
E.Dulcocax
 
(D) 10. Ãö©ó Ischemic Bowel Disease ¤§±Ô­z¡A¤U¦C¦óªÌ¿ù»~¡H (1)Ischemic colitis ³q±`¤£·|«I¥Çrectum¡F(2)Ischemic colitis ±`«I¥Ç¥kÃä¤j¸z¡F(3)Systemic Lupus Erythematosis ¯f¤H¥i¯à¿©±wischemic colitis¡F(4)Chronic mesenteric ischemia¯f¤H¤§¸¡µh³q±`»P¶i­¹µLÃö¡F(5)Chronic mesenteric ischemia ¤SºÙintestinal angina¡F(6)Acute mesenteric ischemia ±`µo¥Í©ó¤¤¦Ñ¦~¤H( > 50·³)¡F(7)SMA (superior mesenteric artery) embolus ¾É­Pªºacute mesenteric ischemia ¯f¤H¡Aµo¯f´Á¶¡¨äplain abdomen ³£¤£·|¦³¥ô¦ó²§±`ªí²{¡C
A.(1)+(2)+(4)
B.(2)+(3)+(6)
C.(3)+(5)+(7)
D.(2)+(4)+(7)
E.(1)+(5)+(6)
 
(B) 11. Ãö©ó obscure gastrointestinal bleeding ¤§½T¶E¡A¤U¦C±Ô­z¦óªÌ¿ù»~¡H
A.À³¦A¥H colonoscopy¤Îesophagogastroduodenoscopy ±Æ°£±`¨£ªº¥X¦å¯f¨_
B.Technetium-99m (Tc-99m) labeled nuclear scan ¥Î©ó°»´ú actively bleeding lesions«Ü¦³¥Î¡A¥u­n¥X¦å¶q¹F 0.1-0.5 mL/min §Y¥i¡A¤]¯à§PÂ_¬°¦óºØ¯f¨_¤Î¨ä¸Ñ­å¦ì¸m¡C
C.Angiography (celiac & mesenteric arteries) ¶È¯à¥Î©ó active overt bleeding ( »Ý > 1 mL/min) ¤§¯f¤H¡A°£¤F¶EÂ_¡A¤]¯à´£¨Ñarterial embolization ªvÀø¡C
D.Small-bowel barium study with enteroclysis ²{¦b¸û¤Ö³Q¥Î¬°²Ä¤@½u¶EÂ_¤u¨ã
E.Single- and Double-Balloon Enterscopy¤£¾A¥Î©ó¦³ radiation enteritis, severe ulceration ¤Î recent bowel surgery ¤§¯f¤H
 
(C) 12. 28·³¨k©Ê¯f±w¦]¬°§]Ã`§xÃø(dysphagia)±µ¨ü¤W®ø¤Æ¹DÄá¼vÀË¡Aµ²ªG¦p¹Ï¡C¤U¦C±Ô­z¡A¦óªÌ¬°¿ù¡H(1)¥u¦³¹ï©TºA­¹ª«·|¦³§]Ã`§xÃø²{¶H¡F(2)¦¹¯fªº²£¥Í¥i¯à»P¿ò¶Ç©ö·P©Ê(genetic susceptibility)¥[¤W²Ä¤@«¬Herpes simplex virus·P¬V¡F(3)­¹¹DÀËÀ£´ú¸Õ(manometry)¬°¦¹¯f³Ì±Ó·PªºÀˬd¡F(4)±o¨ì­¹¹DÀùªº¾÷²v©M¤@¯ë¤H¬Û¦P¡F(5)¥HCalcium channel blockerªvÀø®ÄªG¨}¦n
A.(1)+(2)+(3)
B.(1)+(3)+(4)
C.(1)+(4)+(5)
D.(2)+(3)+(4)
E.(2)+(4)+(5)
 
(B) 13. ±wªÌ¦]¤W¸¡´eµh±µ¨ü¤W®ø¤Æ¹D¤ºµøÃèÀˬd¡Aµo²{¤Q¤G«ü¸z¼ìºÅ¡A­GÃè¤Á¤ù§Ö³t§¿¯ÀúCÀˬd(rapid urease test)§e²{¶§©Ê¡A¯f±w¨Ã¥¼ªA¥Î®øª¢¤îµh¾¯¡A¦ý¹ï½L¥§¦èªL(penicillin)¹L±Ó¡C¸gªA¥Î14¤Ñomeprazole¡Bmetronidazole¤Îclarithromycin«á¡A±µ¨ü§¿¯À©I§l´ú¸Õ(urea breath test)µ²ªG¶§©Ê¡A°£¤F¦A«×µ¹¤©½è¤lÀ°®ú§í¾¯(proton pump inhibitor)¥~¡A¤U¦C¦ó¶µ³B¤è³Ì¾A¦X¦¹¦ì±wªÌ¡H
A.amoxicilin©Mlevofloxacin
B.bismuth subsalicylate, metronidazole©Mtetracycline
C.clarithromycin©Mamoxicillin
D.clarithromycin©Mmetronidazole
E.trimethoprim-sulfamethoxazole©Merythromycin
 
(C) 14. ¦³ÃöÁx»Ä(bile acid)±Ô­z¡A¦óªÌ¬°¬O¡H(1)Áx»Ä¥D­n¥Ñ¨xŦ¦X¦¨¦Ó¨Ó¡A¿¯­¹(diet)¤¤¨ÃµLÁx»Ä¦¨¥÷¡F(2)¦¸¯Å(secodary)Áx»Ä¥]¬Achenodeoxycholic acid©Mlithocholic acid¨âºØ¡F(3)Áx»Ä¤Àªc¦Ü¸z¹D«á¥D­n¦b¤j¸z¦A§l¦¬¡F(4)ºC©Ê¨x¯f¡A¦p­ìµo©ÊÁx¹D¨xµw¤Æ(primary biliary cirrhosis)¡A¥i¦]¬°Áx»Ä¦X¦¨¤Î¤Àªc²§±`³y¦¨¯×ªÕ©Ê¸¡Âm(steatorrhea)¡F(5)Áx»Ä¦X¦¨¥D­n¨üÁx©T¾Jdegradation»Ã¯À7£\-hydroxylase½Õ±±
A.(1)+(2)+(3)
B.(1)+(3)+(4)
C.(1)+(4)+(5)
D.(2)+(3)+(4)
E.(2)+(3)+(5)
 
(E) 15. 20·³¨k©Ê¡A¸¡Âm¶W¹L1­Ó¤ë¡A¤j«K±aÂH²G¤Î¦å²G¡A¥B¥X²{Ãö¸`¯kµh²{¶H¡A¦³¥Ö½§¯f¨_(¦p¹Ï)¡A³Ì¥i¯àªº¶EÂ_¬°¡H
A.¤j¸z¿EÀê¯g(irritable bowel syndrome)
B.ªA¥Î§Ü¥Í¯À¤Þ°_¤§¸zª¢
C.ºC©Ê¯ØŦª¢
D.¤p¸z±H¥ÍÂηP¬V¡A¦pGiardia
E.§J¶©¤ó¯g(Crohn's disease)
 
(A) 16. 34·³¤k©Ê¦]«ùÄò©Ê¤W¸¡µh¤Ï®g¦Ü­I³¡¡Bäú¤ß¡B¹Ã¦R5¤Ñ¡A¶EÂ_¬°°sºë¬ÛÃö¯ØŦª¢¦Ó¦í°|±µ¨ü¶i¤@¨Bµû¦ô¡C¨­ÅéÀˬdÅé·Å38.2¢J¡A¦åÀ£132/84mmHg¡B¯ß·i101/min¡B©I§l20/min¡B¾d½¤µL¶ÀÁx¡B¸¡³¡Äjº©©ÊÀ£µh¥B¸z­µ¬°hypoactive¡C¦å²GÀˬdWBC:15400/£gL¡BAST:189U/L¡BALT:151U/L¡BBilirubin(total):1.1mg/dL¡Bamylase:388U/L¡Blipase:924U/L¡C¹q¸£Â_¼hÅã¥Ü¯ØŦÄjº©©Ê¤ô¸~¡A¥B¦³peripancreatic fluid collection¡A¦ýµLÃa¦º²{¶H¡C³Ì¾A¦Xªº¤U¤@¨BªvÀø¬°¦ó¡H
A.enteral nutrition by nasojejunal feeding tube
B.intravenous imipenem
C.pancreatic debridemet
D.parenteral nutrition
E.oral metronidazole
 
(D) 17. 68·³¨k©Ê¦³³¤°s¯f¥v¡A¦]¶¡·²©Ê¸¡µh¦X¨Ö¸¡Âm7­Ó¤ë¦Ü«æ¶E¡A¯f±w¨Ã¥¼ªA¥Î¥ô¦óÃĪ«¡C¨­ÅéÀˬd¨ÃµLµo¿N¡ABP:108/72mmHg¡B¯ß·i:80/min¡B©I§l16/min¡A¨{¤l¨ÃµLÀ£µh¤]¥¼¦³¸¡µÈ¡C¦å²GÀˬdAST:155U/L¡BALT:88U/L¡BALP:96U/L¡BBilirubin(total):1.1mg/dL¡Bamylase:65U/L¡Blipase:70U/L¡CÁT«KÀˬd¦³¯×ªÕ¡A¸¡³¡¹q¸£Â_¼h¦p¹Ï¡A¤U¦C¦óªÌ¬°¥¿½TªvÀø¡H
A.fiber
B.cholestyramine
C.loperamide
D.pancreatic enzyme
E.ciprofloxacin
 
(B) 18. 81·³°ü¤k¦³3­Ó¤ë¸¡µh¤Î­Iµh¡A¦X¨Ö­¹¼¤¤£®¶¤ÎÅé­«´î»´11¤½¤ç¡A³Ìªñ2¶g¥X²{¶À¯n¤Î¥Ö½§·kÄo¡C¦å²GÀˬdWBC:13200/£gL¡BBilirubin(total):12.4mg/dL¡BALP:784U/L¡BCA19-9:822U/L¡C¸¡³¡¹q¸£Â_¼h©ó¯ØŦÀY¦³3.2¤½¤À¸~½F¦X¨Ö¯ØºÞ©MÁxºÞÂX±i¤Î¨xŦ¦hÁû¸~½F¡A¤ºµøÃè¶W­µªi¦X¨Ö¯ØŦÀY³¡¸~½F¤Á¤ù¤§¯f²z¬°¸¢Àù(adenocarcinoma)¡C¤U¦C¦ó¶µ³B¸m¹ï¯f±w³Ì«ê·í¡H
A.¨xŦ¤Á¤ù
B.Áx¹D¤ä¬[¸m©ñ
C.¯ØŦ©M¨xŦ©ñ®gªvÀø
D.¤â³N¤Á°£¯ØŦ¸~½F
E.»²§U©Ê¤Æ¾ÇªvÀø
 
(D) 19. 57·³¤k©Ê¦]«æ©Ê¥ª¤U¸¡µh¡B¸¡Âm¡Bäú¤ß¦Ü«æ¶E¡AÅé·Å38.1¢J¡ABP:115/76mmHg¡B¯ß·i:98/min¡A¥ª¤U¸¡¦³«öÀ£µh¡A¦ýµL¤Ï¼uµh¤]µL¸~¶ô¡CWBC:14900/£gL¡A¸¡³¡¹q¸£Â_¼hÅã¥Ü¤Aª¬µ²¸z¦³diverticula¥B¦³pericolic fatty infiltration¤Îbowel wall thickening¡C¦ýµLÁwºÅ¡Bªý¶ë©ÎὺޡC¤U¤@¨B³Ì¾A·í³B¸m¬°¡H
A.¤Aª¬µ²¸zÃèÀˬd
B.¥þ¤j¸zÃèÀˬd
C.¤fªAcephalexinªvÀø
D.¤fªAciprofloxacin©MmetronidazoleªvÀø
E.¥~¬ì¤Á°£
 
(E) 20. 30·³¨k©Ê¡A4¦~«e³Q¶EÂ_B«¬¨xª¢¡A³Ìªñ3¶g¦³¯h­Â¡B¶ÀÁx²{¶H¡C¯f±w°¸º¸³Ü¤@²~°à°s¡A¨ÃµLªA¥Î¥ô¦óÃĪ«¡C¨­ÅéÀˬd:Åé·Å36.1¢J¡B¦åÀ£120/65mmHg¡B¯ß·i100/min¡B©I§l16/min¡A¥k¤W¸¡¦³»´«×À£µh¡C¦å²GÀˬd:Bilirubin(T)/(D):3.8/1.8mg/dL¡BAST:1100U/L¡BALT:1450U/L¡BPT INR:1.2¡BHBsAg(+)¡BIgG-anti-HBc(+)¡BIgM-anti-HBc(-)¡BHBV-DNA<20U/L¡Banti-HCV(-)¡A¶W­µªi¶Èµo²{¨xŦ¹ê½è¬°heterogeneous echotexture¡AµL¨ä¥¦²§±`¡C¦¹¯f±w³Ì¥i¯à¶EÂ_¬°¡H
A.«æ©Ê°sºë©Ê¨xª¢
B.«æ©ÊÁxÅnª¢
C.¨x²Ó­MÀù
D.B«¬¨xª¢¯f¬r¦A¬¡¤Æ(reactivated HBV infection)
E.D«¬¨xª¢¯f¬rsuperinfection
 
(C) 21. 51·³¨k©Ê¦]¥b¦~äú¤ß¡B¸¡µÈ¡B©M¸¡Âm¤J°|Àˬd¡Cäú¤ß©M¸¡µÈ¦b¶º«á¤@¤p®Éµo¥Í¥B¦X¨Ö¿E¯P¸z¤lį°Ê¤Î¤ß±ª¡C°ª¯×¶¼­¹¨Ã¤£·|¥[­«¯gª¬²£¥Í¡A¤]¨S¦³¸¡µh©ÎÅé­«´î»´¡C­Ó®×9­Ó¤ë«e¦]perforated peptic ulcer±µ¨üdistal gastrectomy¤â³N¡A³N«á¨Ã¥¼ªA¥ÎÃĪ«¡C¨­ÅéÀˬdBMI:24¡A¥Í©R¼x¶Hí©w¥B¥¿±`¡A¸z­µ¬°hyperactive¡C¦å²GÀˬd¥]¬ACBC©M¥Í¤Æ§¡¥¿±`¡C¤W®ø¤Æ¹D¤ºµøÃèµo²{¤â³N§k¦X³B¥¿±`¥BºZ³q¡A¤Á¤ù¤Î¤p¸z²G¤ÀªR¤]¥¿±`¡C³Ì¥i¯àªº¶EÂ_¬°¡H
A.carcinoid syndrome
B.chronic mesenteric ischemia
C.dumping syndrome
D.gastrinoma
E.irritable bowel syndrome
 
(D) 22. 75·³¤k©Ê¤@¦­°_§É¦³¸¡³¡µ±µh¡B¸¡Âm¤G¦¸¡A¥B¦X¨Ö¸Ñ¥XÂA¦å¡C¯f±w¦³°ª¦åÀ£¤Î«aª¬°Ê¯ß¯e¯f¯f¥v¡AªA¥ÎÃĪ«¥]¬Aaspirin, ramipril, metoprolol©Msimvastatin¡C6­Ó¤ë«e¤j¸zÃèÀˬd¥¿±`¡C¦Ü«æ¶E¤§¨­ÅéÀˬdÅé·Å36.8¢J¡B¦åÀ£130/80mmHg¡B¯ß·i70/min¡B©I§l14/min¡A¥ª¤U¸¡¦³À£µh¡Aª½¸z¨z¶E¦³ÂA¦å¡C¸¡³¡¹q¸£Â_¼h¤§¤Aª¬µ²¸z¦³§½³¡¼W«p²{¶H¡C¤U¦C¦óªÌ¬°³Ì¥i¯àªº¶EÂ_¡H
A.Crohn's disease
B.ulcerative colitis
C.microscopic colitis
D.ischemic colitis
E.CMV colitis
 


< ¤@¢¯¤»¦~«×¸ÕÃD¥Ø¿ý >